Intas Pharma and Meiji and Dong-A St sign commercialisation agreement for ustekinumab biosimilar

Jul 22, 2021

Intas Pharma announced it has signed a commercialisation agreement with Meiji and Dong-A St for DMB-3115 (proposed ustekinumab biosimilar). Under the agreement, Intas will receive exclusive licensing rights to DMB-3115 worldwide excluding Japan, Korea and certain countries in Asia.

Print Page Mail Article